AVB-001

N/A

Report date: 2025/06/12 11:47:11

Base Information

Drug NameAVB-001
Drug Alias NameAVB-001SENT-001
ClassificationCell and gene therapy > Cell therapyCell and gene therapy > Gene therapy
Mechanisms of ActionInterleukin-2 replacements
TargetsInterleukin-2
Therapy Area/IndicationsFallopian Tube NeoplasmsOvarian NeoplasmsPeritoneal Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAvenge Bio Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAvenge Bio Inc
Active IndicationsN/A
Inactive IndicationsFallopian Tube NeoplasmsOvarian NeoplasmsPeritoneal Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A